About Clearside Biomedical, Inc. - Common Stock (CLSD)
Clearside Biomedical is a biopharmaceutical company focused on developing innovative therapies for eye diseases. The company specializes in the delivery of drugs to the back of the eye, utilizing its proprietary suprachoroidal injection platform to enhance treatment efficacy and minimize side effects. Clearside’s pipeline includes formulations targeting conditions such as wet age-related macular degeneration and other retinal disorders, with the aim of providing improved therapeutic options for patients suffering from these debilitating conditions. Through its advancements in ocular drug delivery, Clearside seeks to transform the treatment landscape for various eye diseases. Read More
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
Clearside Biomedical's CLS-AX Phase 2b trial for wet AMD met primary and secondary endpoints, showing stable vision and reduced injection frequency by 84% over 24 weeks, with no serious adverse events reported.
Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS Microinjector and strategic partnerships.
